URN:NBN:SI:doc-LOSGC9TO2014Edelbaher, NatalijaKern, IzidorKovač, ViljemRajer, MirjanaStanič, KarmenVrankar, MartinaZwitter, Matjaždocuments/doc/L/URN_NBN_SI_doc-LOSGC9TO_001.pdfdocuments/doc/L/URN_NBN_SI_doc-LOSGC9TO_001.txt448articlestr. 361-368, III1318-20991882747URN:NBN:SI:doc-LOSGC9TOengAssociation of Radiology and OncologyRadiology and oncology (Ljubljana)BYcisplatinEGFR activating mutationserlotinibgemicitabingemicitabinenedrobnocelični raknon-small cell lung cancerpljučni rakhigh proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutationsIntercalated chemotherapy and erlotinib for advanced NSCLC